Autolus Therapeutics plc (AUTL) is priced at $7.00 after the most recent trading session. At the very opening of the session, the stock price was $6.90 and reached a high price of $7.0981, prior to closing the session it reached the value of $7.50. The stock touched a low price of $6.52.
Recently in News on February 10, 2021, Autolus Announces Pricing of Public Offering. Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in the United States of 14,285,715 American Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares at a public offering price of $7.00 per ADS, for total gross proceeds of approximately $100.0 million. All ADSs sold in the offering were offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 12, 2021, subject to customary closing conditions. You can read further details here
Autolus Therapeutics plc had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $9.98 on 01/07/21, with the lowest value was $6.52 for the same time period, recorded on 02/10/21.
Autolus Therapeutics plc (AUTL) full year performance was -31.37%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Autolus Therapeutics plc shares are logging -59.28% during the 52-week period from high price, and 133.33% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $3.00 and $17.19.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 8438028 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Autolus Therapeutics plc (AUTL) recorded performance in the market was -21.70%, having the revenues showcasing -38.76% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 378.77M, as it employees total of 290 workers.
Specialists analysis on Autolus Therapeutics plc (AUTL)
During the last month, 9 analysts gave the Autolus Therapeutics plc a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 10.26, with a change in the price was noted -7.00. In a similar fashion, Autolus Therapeutics plc posted a movement of -50.00% for the period of last 100 days, recording 239,827 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AUTL is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: Autolus Therapeutics plc (AUTL)
Raw Stochastic average of Autolus Therapeutics plc in the period of last 50 days is set at 8.41%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 16.67%. In the last 20 days, the company’s Stochastic %K was 33.69% and its Stochastic %D was recorded 42.29%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -21.70%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -54.46%, alongside a downfall of -31.37% for the period of the last 12 months. The shares increased approximately by -7.41% in the 7-day charts and went up by -20.09% in the period of the last 30 days. Common stock shares were lifted by -38.76% during last recorded quarter.